Pharmaceutical manufacturers can reduce utility and material costs while lowering environmental impacts by identifying avoidable energy, water, and material use across plants and research facilities. HVAC and building controls, utility systems, water use, and solvent-intensive processes are practical places to look—but projected savings are opportunities, not guaranteed results. Any change must protect product quality, regulatory compliance, and reliable medicine supply.
Where pharmaceutical facilities can find savings
The strongest case for sustainability starts with site-level data, not a broad industry savings promise. The U.S. Department of Energy’s Lawrence Berkeley National Laboratory published a guide in 2008 estimating that the U.S. pharmaceutical industry used almost $1 billion in energy annually. That figure is historical, not a current industry total. The guide organizes efficiency measures at component, process, system, and organizational levels, and stresses that each plant must assess the economics and applicability of a measure while maintaining compliance and product quality. Read the LBNL guide.
As an Amazon Associate I earn from qualifying purchases.
A more detailed example comes from an ISPE case study published in 2020. Assessments conducted at 11 sites in 2017–2018 identified more than 270 project opportunities, representing over $6 million per year in potential savings, or 25% of those sites’ annual utility costs. These are findings from the assessed sites, not a typical result or industry benchmark. In the Company A assessment, HVAC and building-management controls accounted for around half of identified savings. See the ISPE case study.
Start with HVAC and utilities
Heating, ventilation, air conditioning, and building controls can consume substantial energy in pharmaceutical facilities, where environmental conditions and dependable operation matter. The ISPE case study discusses opportunities such as optimizing chilled-water setpoints, improving pump efficiency, using variable flow, tuning systems, and adjusting cooling-tower controls. These changes are not interchangeable: their feasibility depends on the facility’s equipment, operating conditions, and validation needs.
#1 Best Overall
Some operating or behavior changes may require little capital, while equipment upgrades may require investment and planning. A useful assessment looks beyond a projected utility reduction to the implementation cost, expected payback, operational risk, and effort needed to validate a change.
Map water use, including hidden costs
Water can carry costs beyond the water bill. Pumping, heating, filtering, and disposing of it also use energy, equipment, and labor. In an EPA case study at Baxter, a cross-functional team mapped water through a manufacturing process and ranked possible improvements. The EPA recommends accurate data, suitable metrics, and leadership support to carry projects through; simple meters or portable flow meters may help establish where water is used. Read the EPA’s Baxter case study.
A meter is a measurement aid, not proof that a device is appropriate for a validated pharmaceutical process. Measurement methods and equipment must suit the process and applicable quality controls.
Rank #2
Can green chemistry lower costs?
Potentially. Reducing solvent use and waste can also reduce the costs of materials, handling, treatment, and disposal. Pfizer describes its green-chemistry program as aiming to reduce undesirable solvents, eliminate waste, conserve energy, and improve process efficiency and yield. These are program aims, not a guarantee that every redesign will lower costs or work for every product. Pfizer’s green chemistry overview.
The ACS Green Chemistry Institute Pharmaceutical Roundtable likewise discusses waste and water reduction and potential operational cost benefits. Its perspective is useful for identifying technical approaches, but results depend on the chemistry, process, scale, and requirements for the medicine being made. Explore the ACS Pharmaceutical Roundtable.
How to evaluate a proposed project
Compare projects using consistent facility-specific evidence. A measure with attractive utility savings may still be a poor choice if it creates unacceptable validation work, quality risk, or reliability concerns.
| Evaluation factor | What to establish |
|---|---|
| Annual resource savings | Expected reduction in utility use or materials, based on the site’s operating data and stated assumptions. |
| Environmental impact | Likely effects on emissions, water use, and waste, measured against a defined baseline. |
| Capital and payback | Implementation cost and expected financial return; distinguish estimates from measured results. |
| Implementation and validation | Work required to install, test, document, and validate the change. |
| Quality and reliability | Effects on product quality, regulatory compliance, operations, and dependable supply. |
Resource mapping and cross-functional participation can improve the quality of the decision. Include operations, engineering, environmental teams, and relevant quality and regulatory staff early enough to identify constraints before a project is approved. LBNL’s guide emphasizes evaluating measures at individual plants; ISPE’s case study shows how site assessments can surface opportunities that are easy to miss in a high-level review.
Company goals are not the same as demonstrated savings
Amgen says it aims to make its owned and operated facilities and operations carbon neutral by 2027, reduce water use by 40%, and reduce waste sent for disposal by 75%, using 2019 as the baseline. These are company goals, not independently established outcomes. Its account describes incorporating sustainability assessments into major capital projects and lists examples including water recycling and reclamation, HVAC and cooling improvements, LED lighting, solar, automation, and facility design. Amgen also projected that a planned water-reclamation facility would contribute 20–25% of its global water savings; that is a company projection, not a verified result. Read Amgen’s account.
Amgen principal engineer Kelly Clark describes the operating constraint directly: “You can’t simply choose one path forward if it interferes with medicine production or operational reliability.” That constraint applies to efficiency and sustainability projects generally: environmental and financial gains cannot come at the expense of producing safe, quality medicines reliably.
IFPMA, an industry association, describes member-company activity across operational and value-chain emissions, renewable electricity, energy efficiency, recycling, water use, waste, and product design. Its account indicates the range of approaches companies are pursuing, but does not establish a uniform outcome for the sector. See IFPMA’s overview.
What this means for manufacturers
Going green can be a cost-control strategy when it begins with measured resource use and site-specific economics. HVAC and utility optimization, water mapping, and lower-waste chemistry are credible areas to investigate. The scale of the opportunity varies by facility, and case-study savings should not be treated as a forecast for another plant. The right project is one that earns its financial and environmental case while satisfying the facility’s quality, compliance, and supply requirements.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Scan for outdated or missing drivers - takes under a minuteDriver Scan →For manufacturers in Canada, the Government of Canada’s 2026 primer provides an official starting point for net-zero strategy in the pharmaceutical manufacturing context. Its recommendations are not jurisdiction-specific legal requirements for manufacturers elsewhere. Read the Canadian primer.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
